The federal appeals court has issued a ruling that significantly alters the distribution of mifepristone, a drug commonly used in abortions across the United States.
Under the new decision, mifepristone will no longer be available for mailing and can only be obtained in person at designated clinics.
This ruling may impact access to the medication for many individuals seeking abortion services, raising concerns about the implications for reproductive health care.